By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MedImmune 

One MedImmune Way

Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-398-0000 Fax: 301-398-9000


SEARCH JOBS

MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.

With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.

Key Statistics


Email:
Ownership: Public

Web Site: MedImmune
Employees: 3,000
Symbol: AZN
 



Industry
Biotechnology






Company News
MedImmune (AZN) And Juno Therapeutics (JUNO) Announce Immuno-Oncology Clinical Trial Collaboration 4/23/2015 6:32:17 AM
Immunocore Limited And MedImmune (AZN) Announce New Collaboration To Conduct Immuno-Oncology Combination Trails In Melanoma 4/16/2015 6:33:40 AM
Humabs BioMed Reports Clinical Milestone In MedImmune (AZN) Partnership 4/13/2015 9:31:34 AM
MedImmune (AZN) Release: MEDI8897 Receives Fast Track Designation By The FDA For The Prevention Of Respiratory Disease Caused By RSV In Infants 4/9/2015 6:26:28 AM
Investigational New Drug Application For WuXi PharmaTech Co., Ltd. MedImmune (AZN)'s Monoclonal Antibody Accepted For Review By CFDA 3/27/2015 6:21:17 AM
MedImmune (AZN) And Joslin Diabetes Center Announce New Research Collaboration Focused On Advancing Metabolic Disease Research 3/10/2015 8:25:25 AM
AstraZeneca PLC (AZN)'s MedImmune (AZN) Will Provide First-Year Funding for Seven NIST Postdoc Scientists in Unique R&D Deal 2/23/2015 6:16:44 AM
MedImmune (AZN) And The AstraZeneca PLC (AZN) Announce Partnership To Advance Protein Formulation Science 2/5/2015 2:45:29 PM
MedImmune (AZN) Release: First Patient Enrolled In The New Drugs 4 Bad Bugs Program 2/2/2015 11:20:39 AM
MedImmune (AZN) Establishes Three-Year Partnership With National Cancer Institute To Advance Oncology Research 1/21/2015 9:32:53 AM
12345678910...
//-->